Hormonal Treatment of Transgender Women with Oral Estradiol

The document reviewed the hormonal treatment of transgender women using oral estradiol, focusing on its effectiveness and safety. It analyzed data from 166 transgender women over 10 years, finding that oral estradiol effectively increased serum 17-β estradiol levels in 90% of participants, though there was significant variability in the required dose. Spironolactone impaired estradiol levels and did not aid in testosterone suppression, while finasteride increased testosterone levels. The study emphasized the importance of individualized treatment plans and regular monitoring to manage potential risks, such as thromboembolic events, and to optimize hormone therapy outcomes.